 |
Wenxin Zheng, M.D., tenure Professor of Pathology and Obstetrics and Gynecology, American board certified pathologist, director of the Gynecologic Pathology and Molecular Pathology program at the University of Arizona, graduated from Shanghai Medical College Fudan University and trained at Columbia University, Cornell University, and Brown University Medical Centers in anatomic pathology and gynecologic pathology. Dr. Zheng is an internationally recognized gynecologic pathologist with expertise in hormonal etiology of sporadic ovarian cancer, type II endometrial carcinogenesis, and hormone replacement therapy.
1982-1986 Intern and resident, Hospital of Obstetrics and Gynecology, Shanghai Medical College Fudan University China
1986-1989 Post Doctoral Scientist, College of Physicians and Surgeons1989-1991 Associate Research Scientist, Columbia University, New York, NY
1991-1995 Intern, Resident and Chief Resident, Pathology, The New York Hospital, Cornell University Medical College, New York, NY,
1995-1996 Gynecologic & Breast Pathology Fellow and Instructor, Department of Women and Infants’ HospitalPathology, Brown University, Providence, RI,
1996-2000 Assistant Professor of Pathology and Gynecology, Attending Pathologist, Department of Pathology University Southern California School of Medicine, Women & Children’s Hospital, Los Angeles, CA
2000-2005 Associate Professor, Director of Gynecologic Pathology and Fellowship for Gynecologic Pathology, Department of Pathology, Yale University School of Medicine,Yale - New Haven Hospital, New Haven, CT
2005-present Tenure Professor of Pathology and Gynecology, Director of Gynecologic and Molecular Pathology, Department of Pathology and Gynecology, The University of Arizona Medical College, University Medical Center and University Physicians Healthcare, Tucson, AZ
2005-2008 Chairman, Professor of Pathology, Gynecology and Oncology, Department of Pathology, Pathology Center, Shanghai Medical College Fudan University, Shanghai, China
(*Corresponding author articles)
36. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, *Zheng W. Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma. Clin Cancer Res 2008; 14: 2263-9 [Pubmed] [PDF]
35. Ulukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, Zheng W, Arici A. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril 2008; March 1 [Pubmed] [PDF]
34. Fadare O, *Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of type II endometrial cancers. Diagn Pathol 2008; 3 [Pubmed] [PDF]
33. *Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The Oncofetal Protein IMP3: A Novel Biomarker for Endometrial Serous Carcinoma. Am J Surg Pathol 2008; 32: 304-15. [Pubmed] [PDF]
32. Yi X, *Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Current Opinion Obstet Gyneco 2008; 20: 20-25. [Pubmed] [PDF]
31. Fadare O, Yi X, Liang SX, Ma Y, *Zheng W. Variations of Mitotic Index in Normal and Dysplastic Squamous Epithelium of the Uterine Cervix as a Function of Endometrial Maturation. Modern Pathol 2007; 20: 1000-8. [Pubmed] [PDF]
30. *Zheng W, Liang SX, Yi XF, Ulukus EC, Davis J, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol 2006; 26: 38-52. [Pubmed] [PDF]
29. Risch HA, Bale AE, Beck PA and Zheng W. PGR +331A/G and Increased Risk of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prevention 2006; 15: 1738-41. [Pubmed] [PDF]
28. Ulukus M, Ulukus EC, Seval Y, Cinar O, Zheng W, Arici A. Expression of interleukin-8 receptors in patients with adenomyosis. Fertil Steril 2006; 85:714-20. [Pubmed] [PDF]
27. Fadare O, Liang SX, E. Cagnur Ulukus EC, Chambers SK, and *Zheng W. Precursors of Endometrial Clear Cell Carcinoma. Am J Surg Pathol 2006; 30: 1519-30. [Pubmed] [PDF]
26. Oluwole Fadare O, Reddy H, Wang J, Hileeto D, Schwartz PE and *Zheng W. E-cadherin and beta-catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World Journal of Surgical Oncology 2005; 3: 38. [Pubmed] [PDF]
25. *Zheng W, Li N, Wang J, Ulukus EC, Murat Ulukus M, Arici A, and Liang SX. Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis. Int J Gynecol Pathol 2005; 24: 164-72. [Pubmed] [PDF]
24. *Zheng W, Schwartz PE. Serous EIC as an early form of UPSC. Recent progress of its pathogenesis and current opinions of clinical management, Gynecol Oncol 2005; 96: 579-82. [Pubmed] [PDF]
23. Fadare O, Zheng W*. Histologic dating of the endometrium: Accuracy, reproducibility, and practical value. Adv Anat Pathol 2005; 12: 39-46. [Pubmed] [PDF]
22. Ma L, Fisk J, Crum CP, Zhang R, Ulukus EC, *Zheng W. Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intraepithelial neoplasia. Am J Surg Pathol 2004; 28: 1474-84. [Pubmed] [PDF]
21. Liang SX, Cheng L, Chambers SK, Zhou Y, Schwartz PE, *Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol 2004; 12: 319-31. [Pubmed] [PDF]
20. *Zheng W, Liang SX, Yu H, Rutherford, T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004; 12: 207-23. [Pubmed] [PDF]
19. Zheng W, Baker HE, Mutter GL. Involution of PTEN-Null Endometrial Glands with Progestin Therapy. Gynecol Oncol 2004; 92: 1008-13. [Pubmed] [PDF]
18. Schwartz PE, and *Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol Oncol 2003; 90: 644-50. [Pubmed] [PDF]
17. *Zheng W, Senturk BZ, Parkash V. Inhibin Immunohistochemical Staining: A practical approach for the surgical pathologist in the diagnosis of ovarian sex cord-stromal tumors. Adv Anat Pathol 2003; 10: 27-38. [Pubmed] [PDF]
16. Wang S, Pudney J, Song J, Mor G, Schwartz PE, *Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia—precursor of endometrial cancer. Gynecol Oncol 2003; 88: 108-17. [Pubmed] [PDF]
15. Wang J, Ling-Chang L, Schwarts PE, Lauchlan SC, *Zheng W. Quantitative analysis of FSHR in ovarian epithleial tumors: a novel approach to explain the field effect of ovarian cancer development in peritoneal cavity. Intl J Cancer 2003; 103: 328-34. [Pubmed] [PDF]
14. Wang J, Luo F, Chen P, Liu P, *Zheng W. VEGF Expression and enhanced production by gonadotropins in ovarian epithelial tumors. Intl J Cancer 2002; 97: 163-67. [Pubmed] [PDF]
13. Amezcua CA, Lu JJ, Stanczyk FZ, *Zheng W. Apoptosis may be an early event of Progestin Therapy for endometrial hyperplasia. Gynecol Oncol 2000; 79: 169-76. [Pubmed] [PDF]
12. Lu JJ, Zheng Y, Kang X, Yuan J-M,. Lauchlan SC, *Zheng W. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000; 79: 158-68. [Pubmed] [PDF]
11. *Zheng W, Lu JJ, Luo F, Zhang L, Cho M, Wang CY, Stanczyk F. Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. Am J Reprod Immunol 2000; 44: 104-13. [Pubmed] [PDF]
10. *Zheng W, Luo F, Lu J, Baltayan A, Press M, Zhang ZF, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer (see comment). Gynecol Oncol 2000; 76: 294-300. [Pubmed] [PDF]
9. *Zheng W, Lu J, Luo F, Zheng Y, Feng Y-J, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by FSH and inhibition of the effect by LH. Gynecol Oncol 2000; 76: 80-8. [Pubmed] [PDF]
8. *Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 as an significant diagnostic marker for uterine surface carcinoma--precursor lesion of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22: 1463-73. [Pubmed] [Fulltext]
7. *Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Schneyer A, Lauchlan SC, Felix JC. Imbalanced expression of inhibin and activin subunits of in primary epithelial ovarian cancer. Gynecol Oncol 1998; 69: 23-31. [Pubmed] [PDF]
6. *Zheng W, Sung CJ, Hanna I, Lambert-Messerlian G, Steinhoff M, Lauchlan SC. Alpha and beta subunits of inhibin/activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol 1997; 16: 263-71. [Pubmed] [PDF]
5. *Zheng W, Sung CJ, Cao P, Cai R, Godwin TA, Kramer EE, Lauchlan SC. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol Oncol 1997; 64: 38-48. [Pubmed] [PDF]
4. *Zheng W, Cao P, Zheng M, Kramer EE, Godwin T. p53 overexpression and bcl-2 persistence in endometrial adenocarcinoma: comparison of serous and endometrioid subtypes (see comments). Gynecol Oncol 1996; 61: 167-74. [Pubmed] [PDF]
3. Zheng W, Magid MS, Kramer EE, Chen YT. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 1996; 148: 47-53. [Pubmed] [PDF]
2. Zheng W, Wolf S, Kramer EE, Hoda S. Borderline serous tumor of the fallopian tube. Am J Surg Pathol 1996; 20: 30-35. [Pubmed] [Fulltext]
1. Zheng W, Butwell T, Hecket L, Griswold M, Bellve AR. Pleiotypic actions of the seminiferous growth factor on two testis cell lines: comparisons with acidic and basic fibroblast growth factors. Growth Factors 1990; 3: 73-82.
Wednesday, April 30, 2008 All contents ©2008 Arizona Board of Regents.
All Rights Reserved.